MedTrace Logo

Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

NCT04609293 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-10-30

No results posted yet for this study

Summary

This trial will explore effectiveness and safety using the combination therapy of camrelizumab，apatinib and hyperfractionated radiotherapy in patients with renal cell carcinoma(RCC). Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.immunotherapy. hyperfractionated radiotherapy, represented by stereotactic body radiation therapy (SBRT), can significantly improve the radiotherapy sensitivity of RCC. This trial will also observe whether SBRT can bring about immune effects and explore the group and individual indicators that affect the treatment effect of RCC.

Conditions

Interventions

COMBINATION_PRODUCT

camrelizumab+apatinib+hyperfractionated radiotherapy

Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Xianshu Gao, MD,PhD · Peking University First Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2023-09-07
Completion
2024-05-07

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609293 on ClinicalTrials.gov